Regulatory T cells expanded by rapamycin in vitro suppress colitis in an experimental mouse model

Haruei Ogino, Kazuhiko Nakamura, tsutomu iwasa, Eikichi Ihara, Hirotada Akiho, Yasuaki Motomura, Kazuya Akahoshi, Hisato Igarashi, Masaki Kato, Kazuhiro Kotoh, Tetsuhide Ito, Ryoichi Takayanagi

研究成果: ジャーナルへの寄稿記事

15 引用 (Scopus)

抄録

Background: To provide rapid immunosuppression without side effects, we analyzed whether rapamycin alone, and regulatory T cells (Tregs) expanded ex vivo by rapamycin, suppressed colitis in a mouse model. Methods: Severe combined immunodeficiency (SCID) mice reconstituted with naive CD4+ T cells were treated with or without intraperitoneal rapamycin. Body weight was evaluated. CD4+ T cells were cultured inthe presence of rapamycin for three 7-day rounds of stimulation. The ratio of Tregs to CD4+T cells was analyzed by flow cytometry. NaiveCD4+T cells were transferred into SCID mice with CD4+ T cells expanded in the presence or absence of rapamycin. Clinical symptoms of colitis, histological changes, and cytokine expression were investigated. Results: Systemic rapamycin partially prevented the development of colonic inflammation in a transfer model of colitis, but decreased body weight in control mice. With rapamycin, stimulated CD4 +T cells expanded eightfold in 3 weeks in vitro, and the proportion of Tregs increased to about 40%. Without rapamycin, CD4+T cells expanded 20-fold in 3 weeks, but the proportion of Tregs remained at about 15%. CD4+ T cells expanded with rapamycin prevented the development of colitis in a naïve CD4+ T-cell transfer model, in association with the down regulation of Th1 and Th17 responses. Conclusions: We demonstrated, for the first time, that CD4+ T cells expanded with rapamycin in vitro suppressed colitis. Therefore, rapamycin-expanded Treg transfer therapy is expected to be efficacious for inflammatory bowel disease.

元の言語英語
ページ(範囲)366-376
ページ数11
ジャーナルJournal of Gastroenterology
47
発行部数4
DOI
出版物ステータス出版済み - 4 1 2012

Fingerprint

Regulatory T-Lymphocytes
Sirolimus
Colitis
Theoretical Models
T-Lymphocytes
Severe Combined Immunodeficiency
In Vitro Techniques
Body Weight
Inflammatory Bowel Diseases
Immunosuppression
Flow Cytometry
Down-Regulation
Cytokines
Inflammation

All Science Journal Classification (ASJC) codes

  • Gastroenterology

これを引用

Regulatory T cells expanded by rapamycin in vitro suppress colitis in an experimental mouse model. / Ogino, Haruei; Nakamura, Kazuhiko; iwasa, tsutomu; Ihara, Eikichi; Akiho, Hirotada; Motomura, Yasuaki; Akahoshi, Kazuya; Igarashi, Hisato; Kato, Masaki; Kotoh, Kazuhiro; Ito, Tetsuhide; Takayanagi, Ryoichi.

:: Journal of Gastroenterology, 巻 47, 番号 4, 01.04.2012, p. 366-376.

研究成果: ジャーナルへの寄稿記事

Ogino, H, Nakamura, K, iwasa, T, Ihara, E, Akiho, H, Motomura, Y, Akahoshi, K, Igarashi, H, Kato, M, Kotoh, K, Ito, T & Takayanagi, R 2012, 'Regulatory T cells expanded by rapamycin in vitro suppress colitis in an experimental mouse model', Journal of Gastroenterology, 巻. 47, 番号 4, pp. 366-376. https://doi.org/10.1007/s00535-011-0502-y
Ogino, Haruei ; Nakamura, Kazuhiko ; iwasa, tsutomu ; Ihara, Eikichi ; Akiho, Hirotada ; Motomura, Yasuaki ; Akahoshi, Kazuya ; Igarashi, Hisato ; Kato, Masaki ; Kotoh, Kazuhiro ; Ito, Tetsuhide ; Takayanagi, Ryoichi. / Regulatory T cells expanded by rapamycin in vitro suppress colitis in an experimental mouse model. :: Journal of Gastroenterology. 2012 ; 巻 47, 番号 4. pp. 366-376.
@article{d445c3105e0f40acaf2ec4f78abe524f,
title = "Regulatory T cells expanded by rapamycin in vitro suppress colitis in an experimental mouse model",
abstract = "Background: To provide rapid immunosuppression without side effects, we analyzed whether rapamycin alone, and regulatory T cells (Tregs) expanded ex vivo by rapamycin, suppressed colitis in a mouse model. Methods: Severe combined immunodeficiency (SCID) mice reconstituted with naive CD4+ T cells were treated with or without intraperitoneal rapamycin. Body weight was evaluated. CD4+ T cells were cultured inthe presence of rapamycin for three 7-day rounds of stimulation. The ratio of Tregs to CD4+T cells was analyzed by flow cytometry. NaiveCD4+T cells were transferred into SCID mice with CD4+ T cells expanded in the presence or absence of rapamycin. Clinical symptoms of colitis, histological changes, and cytokine expression were investigated. Results: Systemic rapamycin partially prevented the development of colonic inflammation in a transfer model of colitis, but decreased body weight in control mice. With rapamycin, stimulated CD4 +T cells expanded eightfold in 3 weeks in vitro, and the proportion of Tregs increased to about 40{\%}. Without rapamycin, CD4+T cells expanded 20-fold in 3 weeks, but the proportion of Tregs remained at about 15{\%}. CD4+ T cells expanded with rapamycin prevented the development of colitis in a na{\"i}ve CD4+ T-cell transfer model, in association with the down regulation of Th1 and Th17 responses. Conclusions: We demonstrated, for the first time, that CD4+ T cells expanded with rapamycin in vitro suppressed colitis. Therefore, rapamycin-expanded Treg transfer therapy is expected to be efficacious for inflammatory bowel disease.",
author = "Haruei Ogino and Kazuhiko Nakamura and tsutomu iwasa and Eikichi Ihara and Hirotada Akiho and Yasuaki Motomura and Kazuya Akahoshi and Hisato Igarashi and Masaki Kato and Kazuhiro Kotoh and Tetsuhide Ito and Ryoichi Takayanagi",
year = "2012",
month = "4",
day = "1",
doi = "10.1007/s00535-011-0502-y",
language = "English",
volume = "47",
pages = "366--376",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Regulatory T cells expanded by rapamycin in vitro suppress colitis in an experimental mouse model

AU - Ogino, Haruei

AU - Nakamura, Kazuhiko

AU - iwasa, tsutomu

AU - Ihara, Eikichi

AU - Akiho, Hirotada

AU - Motomura, Yasuaki

AU - Akahoshi, Kazuya

AU - Igarashi, Hisato

AU - Kato, Masaki

AU - Kotoh, Kazuhiro

AU - Ito, Tetsuhide

AU - Takayanagi, Ryoichi

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Background: To provide rapid immunosuppression without side effects, we analyzed whether rapamycin alone, and regulatory T cells (Tregs) expanded ex vivo by rapamycin, suppressed colitis in a mouse model. Methods: Severe combined immunodeficiency (SCID) mice reconstituted with naive CD4+ T cells were treated with or without intraperitoneal rapamycin. Body weight was evaluated. CD4+ T cells were cultured inthe presence of rapamycin for three 7-day rounds of stimulation. The ratio of Tregs to CD4+T cells was analyzed by flow cytometry. NaiveCD4+T cells were transferred into SCID mice with CD4+ T cells expanded in the presence or absence of rapamycin. Clinical symptoms of colitis, histological changes, and cytokine expression were investigated. Results: Systemic rapamycin partially prevented the development of colonic inflammation in a transfer model of colitis, but decreased body weight in control mice. With rapamycin, stimulated CD4 +T cells expanded eightfold in 3 weeks in vitro, and the proportion of Tregs increased to about 40%. Without rapamycin, CD4+T cells expanded 20-fold in 3 weeks, but the proportion of Tregs remained at about 15%. CD4+ T cells expanded with rapamycin prevented the development of colitis in a naïve CD4+ T-cell transfer model, in association with the down regulation of Th1 and Th17 responses. Conclusions: We demonstrated, for the first time, that CD4+ T cells expanded with rapamycin in vitro suppressed colitis. Therefore, rapamycin-expanded Treg transfer therapy is expected to be efficacious for inflammatory bowel disease.

AB - Background: To provide rapid immunosuppression without side effects, we analyzed whether rapamycin alone, and regulatory T cells (Tregs) expanded ex vivo by rapamycin, suppressed colitis in a mouse model. Methods: Severe combined immunodeficiency (SCID) mice reconstituted with naive CD4+ T cells were treated with or without intraperitoneal rapamycin. Body weight was evaluated. CD4+ T cells were cultured inthe presence of rapamycin for three 7-day rounds of stimulation. The ratio of Tregs to CD4+T cells was analyzed by flow cytometry. NaiveCD4+T cells were transferred into SCID mice with CD4+ T cells expanded in the presence or absence of rapamycin. Clinical symptoms of colitis, histological changes, and cytokine expression were investigated. Results: Systemic rapamycin partially prevented the development of colonic inflammation in a transfer model of colitis, but decreased body weight in control mice. With rapamycin, stimulated CD4 +T cells expanded eightfold in 3 weeks in vitro, and the proportion of Tregs increased to about 40%. Without rapamycin, CD4+T cells expanded 20-fold in 3 weeks, but the proportion of Tregs remained at about 15%. CD4+ T cells expanded with rapamycin prevented the development of colitis in a naïve CD4+ T-cell transfer model, in association with the down regulation of Th1 and Th17 responses. Conclusions: We demonstrated, for the first time, that CD4+ T cells expanded with rapamycin in vitro suppressed colitis. Therefore, rapamycin-expanded Treg transfer therapy is expected to be efficacious for inflammatory bowel disease.

UR - http://www.scopus.com/inward/record.url?scp=84863098198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863098198&partnerID=8YFLogxK

U2 - 10.1007/s00535-011-0502-y

DO - 10.1007/s00535-011-0502-y

M3 - Article

VL - 47

SP - 366

EP - 376

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 4

ER -